Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.

• Tác giả: Bahriye Aktas, Maggie Banys-Paluchowski, Rupert Bartsch, Erik Belleville, Nina Ditsch, Johannes Ettl, Peter A Fasching, Tanja N Fehm, Chloë Goossens, Nadia Harbeck, Andreas D Hartkopf, Manuel Hörner, Christian Jackisch, Wolfgang Janni, Katharina Keller, Hans-Christian Kolberg, Diana Lüftner, Michael P Lux, Frederik Marme, Volkmar Müller, Julia C Radosa, Andreas Schneeweiss, Florian Schütz, Elmar Stickeler, Florin-Andrei Taran, Hans Tesch, Marc Thill, Michael Untch, Manfred Welslau, Achim Wöckel, Rachel Würstlein
• Ngôn ngữ: eng
• Ký hiệu phân loại: 373.236 Lower level
• Thông tin xuất bản: Germany : Geburtshilfe und Frauenheilkunde , 2025
• Bộ sưu tập: NCBI
• ID: 748802

Tóm tắt

This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.